- Home
- TIL vs OBIO Comparison
TIL vs OBIO Comparison
Compare TIL & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- OBIO
- Stock Information
- Founded
- TIL 2018
- OBIO 2017
- Country
- TIL United States
- OBIO United States
- Employees
- TIL N/A
- OBIO N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- TIL Health Care
- OBIO Health Care
- Exchange
- TIL Nasdaq
- OBIO Nasdaq
- Market Cap
- TIL 177.1M
- OBIO 172.1M
- IPO Year
- TIL 2021
- OBIO N/A
- Fundamental
- Price
- TIL $17.27
- OBIO $3.55
- Analyst Decision
- TIL Strong Buy
- OBIO Strong Buy
- Analyst Count
- TIL 5
- OBIO 4
- Target Price
- TIL $100.67
- OBIO $14.00
- AVG Volume (30 Days)
- TIL 97.5K
- OBIO 368.8K
- Earning Date
- TIL 11-13-2025
- OBIO 11-12-2025
- Dividend Yield
- TIL N/A
- OBIO N/A
- EPS Growth
- TIL N/A
- OBIO N/A
- EPS
- TIL N/A
- OBIO N/A
- Revenue
- TIL N/A
- OBIO $2,944,000.00
- Revenue This Year
- TIL N/A
- OBIO $29.26
- Revenue Next Year
- TIL N/A
- OBIO $10.65
- P/E Ratio
- TIL N/A
- OBIO N/A
- Revenue Growth
- TIL N/A
- OBIO 41.61
- 52 Week Low
- TIL $10.80
- OBIO $2.20
- 52 Week High
- TIL $44.50
- OBIO $6.50
- Technical
- Relative Strength Index (RSI)
- TIL 40.68
- OBIO 57.31
- Support Level
- TIL $17.44
- OBIO $3.56
- Resistance Level
- TIL $20.11
- OBIO $4.10
- Average True Range (ATR)
- TIL 1.29
- OBIO 0.32
- MACD
- TIL -0.00
- OBIO -0.01
- Stochastic Oscillator
- TIL 1.61
- OBIO 52.88
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.